Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy

Zhang,Jun; Yang,Jianmin; Han,Xiaomei; Zhao,Zhongsheng; Du,Ling; Yu,Tong; Wang,Huiju

doi:10.3892/ol.2012.703

July 2012 Volume 4 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July 2012 Volume 4 Issue 1

Full Size Image

Article

Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy

Authors:
- Jun Zhang
- Jianmin Yang
- Xiaomei Han
- Zhongsheng Zhao
- Ling Du
- Tong Yu
- Huiju Wang
View Affiliations / Copyright

Affiliations: Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China
Pages: 178-182
|
Published online on: May 4, 2012

https://doi.org/10.3892/ol.2012.703
Expand metrics +

Abstract

Tumor-associated antigens (TAAs) trigger a TAA-specific immune response, thus they are the crux of antitumor immunosurveillance. A major advance in tumor immunology in the last 20 years was marked by the verification that CTL or B-cell epitopes rather than integral TAAs induce immunoreactivity. Previous studies on the correlation between heparanase (Hpa) expression and clinical or pathological features have generally used commercial antibodies against full-length Hpa protein rather than the functional epitopes, and the antigen determinants of such antibodies have not yet been defined. In our investigation of Hpa peptide expression in gastric cancer tissues and its association with tumor invasion, metastasis and prognosis, we analyzed Hpa expression in the tissues of 132 patients with gastric cancer using tissue microarray (TMA) technology and immunohistochemical staining.Three self-developed rabbit polyclonal antibodies against Hpa multiple antigenic peptides (MAP) and one commercial polyclonal rabbit antibody against the 50-8 kDa Hpa heterodimer were used. Clinical and pathological significance was evaluated using the Chi-square test and Kaplan-Meier survival curve analysis. The results demonstrated that the positivity rates using the antibody against MAP2 and the commercial antibody were 60.6% (80/132) and 65.2% (86/132), respectively. No expression of either MAP1 or MAP3 was noted in the cancer tissues of the 132 cases. MAP2 behaved in a similar manner to the commercial antibody in that a higher Hpa expression was observed in the cancer tissues with vessel invasion, serosal involvement, distant metastasis, poor differentiation and TNM stages Ⅲ and Ⅳ. Moreover, the patients with a positive Hpa expression had a far poorer prognosis, with lower one-year and five-year survival rates. Our results demonstrate that in a similar manner to full-length Hpa proteins, MAP2 expression is closely associated with the invasion, metastasis and prognosis of gastric cancer. This finding may be of potential use in clinical therapy and in estimating the prognosis of a tumor.

View Figures

View References

1	Kreuger J, Spilmann D, Li JP, et al: Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol. 174:323–327. 2006. View Article : Google Scholar : PubMed/NCBI
2	Barash U, Cohen-Kaplan V, Dowek I, et al: Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 277:3890–3903. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ilan N, Elkin M and Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI
4	Yang Y, Macleod V, Bendre M, et al: Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 105:1303–1309. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gohji K, Hirano H, Okamoto M, et al: Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer. 95:295–301. 2001. View Article : Google Scholar : PubMed/NCBI
6	Doweck I, Kaplan-Cohen V, Naroditsky I, et al: Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia. 8:1055–1061. 2006. View Article : Google Scholar : PubMed/NCBI
7	Borghaei H, Smith MR and Campbell KS: Immunotherapy of cancer. Eur J Pharmacol. 625:41–54. 2009. View Article : Google Scholar
8	Rammensee HG, Falk K and Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 11:213–244. 1993. View Article : Google Scholar : PubMed/NCBI
9	Sommerfeldt N, Beckhove P, Ge Y, et al: Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res. 66:7716–7723. 2006. View Article : Google Scholar : PubMed/NCBI
10	Amexis G and Yong NS: Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus. Viral Immunol. 20:657–663. 2007. View Article : Google Scholar : PubMed/NCBI
11	Haro I and Gómara MJ: Different approaches to potentiate the immune response induced by a 12-mer synthetic peptide. Curr Protein Pept Sci. 1:125–137. 2000. View Article : Google Scholar : PubMed/NCBI
12	Yang JM, Wang HJ, Du L, et al: Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. Cancer Immunol Immunother. 58:1387–1396. 2009. View Article : Google Scholar : PubMed/NCBI
13	Du L, Wang HJ, Yang JM, et al: T-helper epitope peptide improves immunological effects of the B cell epitopes of human heparanase protein. Chin J Microbiol Immunol. 28:869–872. 2008.
14	Han XM, Wang HJ, Yang JM, et al: Effects of anti-heparanase antibody on the growth and invasion of HCCLM6 human hepatocellular carcinoma cells. Chin J Oncol. 31:10–14. 2009.PubMed/NCBI
15	Ohtawa Y, Naomoto Y, Shirakawa Y, et al: The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum Pathol. 37:1145–1152. 2006. View Article : Google Scholar : PubMed/NCBI
16	Miao HQ, Liu H, Navarro E, et al: Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 13:2101–2111. 2006. View Article : Google Scholar : PubMed/NCBI
17	Vlodavsky I, Ilan N, Naggi A, et al: Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 13:2057–2073. 2007. View Article : Google Scholar : PubMed/NCBI
18	He X, Brenchley PE, Jayson GC, et al: Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 64:3928–3933. 2004. View Article : Google Scholar : PubMed/NCBI
19	Gingis-Velitski S, Ishai-Michaeli R, Vlodavsky I, et al: Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J. 21:3986–3993. 2007. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy

This article is mentioned in:

Abstract

Figure 1

Related Articles